S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis
Publication
, Journal Article
Townsend, MJ; Grover, S
Published in: American Journal of Gastroenterology
October 2021
Duke Scholars
Published In
American Journal of Gastroenterology
DOI
EISSN
1572-0241
ISSN
0002-9270
Publication Date
October 2021
Volume
116
Issue
1
Start / End Page
S740 / S741
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Gastroenterology & Hepatology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Townsend, M. J., & Grover, S. (2021). S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis. American Journal of Gastroenterology, 116(1), S740–S741. https://doi.org/10.14309/01.ajg.0000780144.09245.72
Townsend, Matthew J., and Shilpa Grover. “S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis.” American Journal of Gastroenterology 116, no. 1 (October 2021): S740–41. https://doi.org/10.14309/01.ajg.0000780144.09245.72.
Townsend MJ, Grover S. S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis. American Journal of Gastroenterology. 2021 Oct;116(1):S740–1.
Townsend, Matthew J., and Shilpa Grover. “S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis.” American Journal of Gastroenterology, vol. 116, no. 1, Ovid Technologies (Wolters Kluwer Health), Oct. 2021, pp. S740–41. Crossref, doi:10.14309/01.ajg.0000780144.09245.72.
Townsend MJ, Grover S. S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis. American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health); 2021 Oct;116(1):S740–S741.
Published In
American Journal of Gastroenterology
DOI
EISSN
1572-0241
ISSN
0002-9270
Publication Date
October 2021
Volume
116
Issue
1
Start / End Page
S740 / S741
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Gastroenterology & Hepatology
- 1103 Clinical Sciences